24/7 Market News Snapshot 28 April, 2025 – Portage Biotech Inc. Common Stock (NASDAQ:PRTG)

April 28, 2025

DENVER, Colo., 28 April, 2025 (www.247marketnews.com) – (NASDAQ:PRTG) are discussed in this article.
Portage Biotech Inc. (NASDAQ:PRTG) is experiencing notable momentum in the market, with its stock rising to $11.305, representing a remarkable increase of 33.79% from the previous close of $8.450 during pre-market trading. The sharp uptick is accompanied by a significant trading volume of 1.15 million shares, reflecting strong investor interest. Technical analyses indicate positive upward momentum for the stock, suggesting further potential for appreciation as market participants engage with this dynamic opportunity.

This surge aligns with the announcement of exciting preclinical efficacy results for Portage’s lead product candidate, PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor. The findings, set to be presented by Dr. Luciano Mutti at the American Association for Cancer Research® (AACR) Annual Meeting, demonstrate PORT-7’s promising single-agent activity in a murine model of mesothelioma, surpassing a single-agent anti-PD1 antibody. Notably, when combined with anti-PD1, PORT-7 significantly enhanced therapeutic outcomes, illustrating the potential of this combination approach.

Key data indicates that mice treated with the PORT-7 and anti-PD1 combination developed tertiary lymphoid structures—a promising indicator of a robust immune response—alongside a substantial increase in immune effector cells. These results position PORT-7 as a potentially transformative treatment for mesothelioma, an aggressive cancer with limited existing therapies.

In conjunction with PORT-7, Portage is advancing PORT-6, a selective A2A adenosine receptor inhibitor, with a view to co-administer both compounds in the ongoing ADPORT-601 trial. This innovative trial aims to entirely block adenosine-induced immunosuppression, potentially revolutionizing the effectiveness of immunotherapies for solid tumors. Portage remains at the forefront of cancer treatment advancements, underscoring its commitment to developing cutting-edge therapeutic solutions.

Related news for (PRTG)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.